Phaeophyceae

Other Names

brown algaebrown macroalgaebrown seaweedBruinwierenFucoideaeFucophyceaekelpMelanophyceaePhaeophyta褐藻綱

Synopsis

Phaeophyceae (Brown Algae): A Comprehensive Reference

1. Identity: Taxonomy, Nomenclature, Natural Sources, and Commercial Forms

Taxonomic Classification and Nomenclature

Phaeophyceae — commonly known as brown algae or brown seaweeds — constitute an entire class of multicellular, photosynthetic marine organisms within the kingdom Chromista (phylum Heterokontophyta). The class is also encountered in the literature under its older synonym Phaeophyta and the equivalent term Fucophyceae. Brown algae are characterized by being multicellular and possessing a brown or greenish-brown color, arising from the predominance of the brown pigment fucoxanthin in addition to the green pigments chlorophyll a and c. Among marine plant-like organisms, the brown algae are one of only five lineages of photosynthetic eukaryotes to have evolved complex multicellularity.

Species Diversity and Ecology

There are approximately 2,000 species of brown algae, the vast majority of which are marine. In general, brown algae are larger, and more species are found in colder waters. The roughly 1,500–2,000 species of brown seaweeds are found exclusively in marine environments, are most abundant in polar and temperate waters, with a few species present in the tropics; they include the largest species of seaweed — Durvillaea and kelps — that grow in cold waters. Virtually all commercially relevant biomass worldwide comes from a relatively small number of species in the orders Laminariales and Fucales.

Nutritionally and pharmacologically important genera and species include:

Laminaria spp. (kelp) — also referred to as Saccharina japonica (Kombu)
Fucus vesiculosus (bladderwrack)
Undaria pinnatifida (wakame)
Ascophyllum nodosum (knotted wrack)
Sargassum spp.
Ecklonia cava (a primary source of phlorotannins)
Macrocystis pyrifera (giant kelp)

For centuries, varieties such as kelp (Laminaria), bladderwrack (Fucus vesiculosus), and wakame (Undaria pinnatifida) have been valued for their unique nutritional and therapeutic properties.

Commercial Forms and Preparations

Brown algae have long been used by coastal societies for their nutritive, functional, and technological applications. In commerce and supplementation, Phaeophyceae are available in a range of preparations:

Dried whole thallus — consumed directly as food (kombu, wakame, hijiki, arame)
Powdered whole algae — encapsulated or used as powder in functional foods
Standardized extracts — typically standardized to fucoidan, fucoxanthin, phlorotannin, or alginate content
Isolated polysaccharides — purified fucoidan, alginate, and laminarin, used in both food-grade and pharmaceutical applications
Alginates — food-grade gelling agents widely used as food additives (E400–E405)
Fucoxanthin concentrates — carotenoid-enriched extracts marketed primarily for body weight management

Brown seaweed extract powder is a concentrated powder made from brown macroalgae (Phaeophyceae). Depending on processing, it may function as an iodine-rich mineral ingredient, a polysaccharide extract (fucoidan/alginates), or a carotenoid-focused ingredient (fucoxanthin).

2. Traditional and Historical Use

East Asian Traditions

Brown algae (Phaeophyceae) have been consumed by humans for hundreds of years. Seaweeds play an integral role in traditional Asian cuisine, particularly in China, Japan, and Korea. Ancient Chinese and Japanese herbalists often incorporated brown algae into remedies for thyroid health, utilizing its natural iodine content to support metabolic function and combat goiter. Kombu (Laminaria japonica) has been a staple of Japanese culinary tradition for over a millennium, used as a base for dashi broth as well as a medicinal food. Wakame (Undaria pinnatifida) features prominently in both Japanese and Korean cuisine, including as an ingredient in miso soup. These kelp species are extensively farmed in East and North Asia (e.g., China, Japan, and Korea) for human and animal consumption, as well as for their biochemical content.

European Folk Medicine

In European folk medicine, brown algae was consumed to promote digestion, relieve constipation, and as a general tonic for vitality and longevity. Bladderwrack (Fucus vesiculosus) was historically used by herbalists in western Europe as a thyroid remedy — recognized for its high iodine content — as well as a topical preparation for joint inflammation. Cell walls of brown algae are composed of cellulose layers separated by polysaccharides such as the precious alginic acid; they are also used to manufacture alginates, which are used as food additives and in other industries.

Indigenous and Pacific Cultures

Kelps have remained part of the culture and histories of coastal peoples, being transmitted through oral tradition, as in the Māori myth of Hine-nui-i-te-pō, described as having kelp-like hair. Indigenous peoples along the Pacific coasts of North America have consumed kelp as food for millennia. Kelp forests play a crucial role in coastal fisheries, which benefit local communities not just by providing food but also through tourism.

Industrial and Agricultural Applications

Today, brown algae are used in the production of fertilizers and feed for the agriculture and aquaculture industries, as a current and future food source for an increasing human population, and for the production of various industrial compounds.

3. Key Constituents and Active Compounds

Overview of Phytochemical Composition

Advances in analytical chemistry and biochemistry have allowed the identification of an extensive range of compounds in brown algae, from bioavailable proteins and trace nutrients to ω-3 fatty acids, dietary fibers, antioxidant phenolic compounds, and polysaccharides with a wide range of beneficial biological activities. Brown algae contain vitamins C, B1, B2, B6, and B12, minerals such as iron, calcium, and magnesium, and trace elements including chromium, zinc, selenium, and iodine, as well as oils, cellulose, mucilage, and bitter tonic substances.

Polysaccharides

Polysaccharides are the main constituents of brown algae; their diverse structures allow many unique physical and chemical properties that help to moderate a wide range of biological activities, including immunomodulation, antibacterial, antioxidant, prebiotic, antihypertensive, antidiabetic, antitumor, and anticoagulant activities.

Alginate

Alginate is the predominant polysaccharide component found in the cell walls and intercellular matrix of brown macroalgae. Chemically, it is composed of (1→4)-β-D-mannuronic acid (M) and (1→4)-α-L-guluronic acid (G) units. Sodium alginate in algae is converted into free alginic acid in the gastrointestinal tract, forming a gel that is not absorbed in the small intestine and binds to dietary cholesterol, increasing its excretion and consequently reducing the amount of cholesterol absorbed in the intestinal lining. Alginates have been shown to inhibit the digestive enzymes pancreatic lipase and pepsin and diminish the intestinal absorption of triacylglycerols, cholesterol, and glucose. Alginate also has antidiabetic activity, which can modulate the glycemic rate by inhibiting α-amylase and α-glucosidase enzymes involved in carbohydrate digestion, and the reduction in the postprandial glucose spike is a result of the delay in starch breakdown.

Fucoidan

Fucoidan is a sulfated polysaccharide found in the cell walls of many species of brown seaweed. The reported bioactivities of fucoidans are diverse and include anticoagulation, blocking of lymphocyte adhesion and invasion, inhibition of multiple enzymes, induction of apoptosis, antiviral activity, and, most importantly, a substantial anti-inflammatory activity. Laminarin, a β-glucan composed of glucose linked by β-1,3 and β-1,6 glycosidic bonds, and fucoidan, a sulfated polysaccharide, both demonstrate strong biocompatibility, low toxicity, and the ability to modulate cellular behaviors. Fucoidan is a family of sulfated polysaccharides; structure varies by species and process.

Laminarin

Laminarin, or β-glucan, a storage polysaccharide from brown algae, has been reported to have potential pharmacological properties such as antioxidant, anti-tumor, anti-coagulant, anticancer, immunomodulatory, anti-obesity, anti-diabetic, anti-inflammatory, wound healing, and neuroprotective potential. Pre-clinical studies show that the non-sulfated alginate and laminarin are well-fermented by gut microbiota, promoting the formation of short-chain fatty acids (SCFAs) including butyrate, and preventing the formation of harmful putrefactive compounds.

Carotenoids: Fucoxanthin

Fucoxanthin is the principal carotenoid pigment of Phaeophyceae and is responsible for the class's characteristic brown-to-olive coloration alongside chlorophyll. Recent studies have reported that fucoxanthin has many physiological functions and biological properties, such as antiobesity, antitumor, antidiabetes, antioxidant, anti-inflammatory, and hepatoprotective activities, as well as cardiovascular and cerebrovascular protective effects. Fucoxanthin, a brown-seaweed-extracted carotenoid, has exhibited anti-obesity properties in some clinical trials through its ability to overexpress uncoupling protein (UCP1) in white adipose tissue, which leads to fat burning.

Phlorotannins

Phlorotannins are one of the main compounds commonly isolated from brown seaweeds. Their structural unit is made up of polyphenolic units, and due to their unique structures, phlorotannins show a variety of biological activities such as antibacterial, antioxidant, anti-inflammatory, antiproliferative, antitumor, antidiabetic, radioprotective, antiadipogenic, and anti-allergic effects. The term "phlorotannins" refers to a group of compounds that include dieckols, eckols, dioxinodehydroeckols (eckstolonols), florofucofuroeckol-A, 7-floroeckol, 8,8′-bieckol, fucofuroeckol-A, and 6,6′-bieckol.

Sterols

Fucosterol has long been known as the predominant sterol of Phaeophyceae, a finding confirmed across numerous studies. Additional minor sterols isolated from brown algae species include stigmasta-5,28-dien-3β-ol, 24-ketocholesterol, and saringosterol.

Minerals: Iodine and Macroelements

Iodine is prominent in seaweed; this essential micronutrient is required for the synthesis of thyroid hormones and the prevention of iodine deficiency-related conditions. Seaweeds also represent one of the few vegetable sources of vitamin B12, highlighting their potential value in plant-based diets.

Pigments

Brown algae possess fucoxanthin, which allows them to absorb light in the blue-green range, facilitating growth at greater depths where light supply is limited; in addition to fucoxanthin, chlorophyll a, chlorophyll c, carotenoids, and other xanthophylls also exist. They contain chlorophylls a and c, as well as carotenes and xanthophylls; some species have been found to contain tocopherol at concentrations of 2.5–3.5 mg% dry matter.

4. Scientific Evidence by Area of Use

4.1 Metabolic Syndrome, Blood Glucose Regulation, and Type 2 Diabetes

Polysaccharides such as alginate and fucoidan have been suggested to assist in increased cholesterol excretion through gel formation within the intestine. Numerous in vitro and in vivo studies have validated antidiabetic mechanisms of seaweed, including the inhibition of α-glucosidase and α-amylase activity, which are enzymes responsible for breaking down starch and other substances into glucose during digestion.

Human/clinical evidence: Human studies that investigated the effect of marine algae (seaweed) on glycemic control are limited; however, desirable effects have been shown in some clinical studies. Lee et al. conducted a randomized clinical trial on 73 male and female participants with fasting blood glucose between 100 and 180 mg/dL, divided into groups given 500 mg of AG-dieckol (a phlorotannin from Ecklonia cava) three times a day for 12 weeks. The result showed an acute significant reduction in postprandial glucose (p < 0.05) after 12 weeks, although non-significant postprandial insulin reduction was seen in the intervention group compared to placebo. Randomization, blinding, and participants' compliance measurement were not reported in this study, which may impact the quality of the findings.

A separate study investigated the acute effects of brown algae extracts (Ascophyllum nodosum and Fucus vesiculosus) on postprandial glucose and insulin concentration; participants were given 508 mg brown algae extract 30 minutes prior to 110 g carbohydrate consumption. Acute insulin concentration was significantly decreased (p < 0.05) in the brown algae group compared to placebo, while the postprandial glucose concentration showed a non-significant decrease. However, the evidence base relies mainly on cell line and small animal models, with few studies to date involving humans.

4.2 Body Weight and Obesity

Fucoxanthin is the primary constituent investigated for anti-obesity effects. Its proposed mechanism is overexpression of uncoupling protein-1 (UCP-1) in white adipose tissue, thereby increasing thermogenesis and energy expenditure.

Key human clinical trial: A 16-week clinical trial involving 151 obese women used Xanthigen, a dietary supplement composed of brown seaweed extract containing 2.4 mg of fucoxanthin combined with pomegranate seed oil. The results confirmed significant weight loss and reduction of abdominal circumference in subjects whose body mass index (BMI) was over 30 kg/m². Daily administration of 600 mg of extract containing 2.4 mg of fucoxanthin per day resulted in significant weight loss compared with placebo after 16 weeks. The authors also reported increases in resting energy expenditure, decreases in body and liver fat content, and improvements in the plasma lipid profile. Weight reductions were approximately 5 kg more in the supplemented group compared with the placebo group.

Evidence quality: Despite much pharmacological evidence from in vitro and in vivo findings, fucoxanthin in clinical research is still not satisfactory, as only one clinical study on obesity management was reported in the last five years reviewed. Since the clinical trials apply pure fucoxanthin or standardized extracts rather than fucoxanthin-bearing dietary supplements in general, a critical analysis is warranted to quantify the fucoxanthin content in commercial brown seaweeds to validate their rationale in weight loss. Overall, the clinical evidence for fucoxanthin's anti-obesity effect remains preliminary and based on very limited human data.

4.3 Cardiovascular Health and Cholesterol

Brown algae and their metabolites — such as carotenoids, polysaccharides, phlorotannins, and proteins — have been associated with multiple beneficial health effects for cardiovascular diseases, one of the main causes of death in Europe. Algae polysaccharides have shown the capacity to decrease blood lipid and total cholesterol levels, while increasing HDL-cholesterol levels.

Among different brown seaweed species, Ascophyllum nodosum and Fucus vesiculosus have the highest antioxidant values and highest total phenolic content. There is some, however, limited evidence that seaweed consumption may offer protective benefits against cardiovascular diseases, diabetes mellitus, and hypertension. As with the metabolic syndrome research generally, the evidence base for direct cardiovascular effects in humans remains largely preclinical.

4.4 Immunomodulation and Cancer (Fucoidan)

Both laminarin and fucoidan have exhibited potential in cancer therapy — laminarin by inducing apoptosis and fucoidan through its anti-angiogenic and immune-modulating properties.

Systematic review evidence (human studies): A systematic review (Cochrane, PubMed, Embase, CINAHL) identified four eligible studies — one randomized controlled trial and three quasi-experimental studies — with a total sample size of 118 participants, most of whom were metastatic colorectal and gastric cancer patients. Meta-analysis was not applied due to heterogeneity of measurement tools. Two studies revealed a significantly longer survival time and chemotherapy treatment periods with fucoidan use. Positive but insignificant effects on disease control rate, inflammatory markers, nutrition status, fatigue, and financial difficulty were shown in those using fucoidan. The results of this systematic review indicate that the effects of fucoidan were inconsistent with clinical outcomes in metastatic or recurrent cancer patients. Only four studies were included, and heterogeneity in methodologies and relatively small sample sizes limited the research consensus. Although a cause-and-effect relationship between fucoidan and survival time or disease control could not be confirmed, this review included the most research on fucoidan in humans to that date.

In animal experiments, all studies indicated anti-cancer effects of fucoidan, including anti-inflammation, anti-oxidation, anti-aging, cholesterol lowering, and blood sugar stabilization. However, fucoidan research in humans is sparse.

Evidence quality: In vitro and animal data are substantial. Human oncology data are very limited, with small, heterogeneous studies. No high-quality RCTs of sufficient size have been completed.

4.5 Gastrointestinal Health and Gut Microbiota

Fucoidan and laminarin intervention modulated the gut microbiota profile including the altered richness of Muribaculaceae, Lachnospiraceae, and Streptococcus; results indicated that these polysaccharides may restore the rhythm of the migrating motor complex and regulate gut microecology. This evidence is currently derived from preclinical (animal) models.

In a mouse model of chronic colitis, orally delivered fucoidan (from Cladosiphon) downregulated levels of the pro-inflammatory cytokine IL-6. Similarly, in a rat model of acute colitis, an orally delivered polysaccharide food supplement containing fucoidan reduced monocyte numbers and improved clinical markers of colitis. These findings are preclinical and have not yet been replicated in adequately powered human clinical trials.

4.6 Antioxidant and Anti-inflammatory Activity

Multiple health benefits have been ascribed to brown seaweeds used traditionally as a dietary component, mostly in Asia. Despite the great diversity of experimental systems in which distinct species and compounds were tested, a remarkably homogeneous picture is apparent: the predominant effects can be classified into inhibition of reactive oxygen species, known to be important drivers of inflammation; and regulation — in most cases inhibition — of proinflammatory NF-κB signaling.

In addition to their antioxidant properties, phlorotannins are closely related to numerous inflammatory events, being capable of inhibiting the expression of pro-inflammatory cytokines, regulating the expression and/or activity of important enzymes, and even interfering with transcriptional regulation, making them promising therapeutic agents for mitigating inflammation and inflammatory-related diseases. The antioxidant activity and ability to inhibit enzymes involved in the production of eicosanoids (phospholipase A2, COX, and LOX) contribute to the anti-inflammatory properties of phlorotannins, leading to a decrease in the production of prostaglandins and leukotrienes.

Evidence quality: Anti-inflammatory and antioxidant activity is well-supported in in vitro cell culture models and some animal studies. Direct human clinical trial evidence for inflammatory conditions is, as of the most recent reviews, limited.

4.7 Thyroid Health (Iodine)

While seaweeds are a valuable nutritional source of iodine — certain types of brown seaweeds such as Laminaria and Saccharina genus (Kombu) contain very high iodine levels — both deficient and excess iodine can have adverse impacts. Iodine content of brown algae is an established and well-characterized nutritional contribution, though this is distinct from pharmacological activity. The relationship between brown algae consumption and thyroid function has been studied in Japanese populations where high dietary seaweed intake is customary.

4.8 Exercise Performance and Muscle (Fucoidan)

Fucoidan extracted from brown algae has been shown to improve aerobic capacity and increase muscle size and strength in mice, but whether these beneficial effects translate to humans is unknown. One study investigated the effect of a resistance training program in combination with fucoidan supplementation on measures of strength and performance in apparently healthy adults. In a double-blind, placebo-controlled design, 20 participants (9 male and 11 female) were randomized to supplement with fucoidan (N = 10, 1 g/day) or placebo (N = 10, 1 g/day) during six weeks of resistance training, with body composition, muscle strength, anaerobic performance, and blood measurements compared pre- and post-training. This trial was small and its results remain exploratory; no strong conclusions can be drawn from a sample of this size.

4.9 Nonalcoholic Fatty Liver Disease (NAFLD)

Research on the preventative effects of fucoxanthin on NAFLD has been reviewed from the perspective of human clinical trials, animal experiments in vivo, and in vitro cell investigations, using a variety of experimental designs, with positive effects demonstrated across models. Pharmaceutical treatment for NAFLD has not yet received approval from the FDA, and currently no effective pharmacological treatments for NAFLD exist beyond weight loss. Most evidence for brown algae constituents in NAFLD is preclinical, though fucoxanthin's effects on liver fat content were also noted in the Abidov et al. obesity trial described above.

5. Body Systems Associated with Phaeophyceae

Endocrine / Thyroid: Iodine content supports thyroid hormone synthesis; relevant to both deficiency correction and excess-intake risk.
Cardiovascular: Cholesterol modulation (via alginate), antihypertensive polysaccharide activity, anticoagulant effects (fucoidan), cardioprotective polyphenols.
Metabolic / Glycemic: Inhibition of α-glucosidase and α-amylase (alginate, phlorotannins, fucoidan), postprandial glucose attenuation.
Gastrointestinal: Prebiotic fermentation of alginate and laminarin; fucoidan effects on gut motility and gut microbiota composition.
Immune System: Immunomodulatory activity of fucoidan and laminarin through pattern recognition receptor engagement and cytokine modulation.
Adipose Tissue / Body Composition: Fucoxanthin UCP-1 upregulation in white adipose tissue; visceral fat reduction.
Hepatic: Fucoxanthin hepatoprotective activity; alginate modulation of lipid absorption relevant to NAFLD.
Skin / Integumentary: Phlorotannins and fucoidan studied for atopic dermatitis and topical anti-inflammatory applications.
Oncology (adjunctive/preclinical): Fucoidan anti-angiogenic and immune-modulating properties; laminarin pro-apoptotic properties in cell-line models.

6. Dosage Forms and Dosages Reported in Studies

The following dosages reflect those specifically reported in published studies; they are not recommendations.

Fucoxanthin (anti-obesity, clinical trial): A 16-week clinical trial with 151 obese women used a supplement containing 2.4 mg of fucoxanthin combined with pomegranate seed oil. The supplement was delivered as 600 mg of brown seaweed extract standardized to that fucoxanthin content.
Phlorotannin AG-dieckol (glycemic control, clinical trial): Participants were given 500 mg of AG-dieckol three times a day for 12 weeks.
Brown algae extract for postprandial glycemia (Ascophyllum nodosum / Fucus vesiculosus): Participants were given 508 mg brown algae extract 30 minutes prior to 110 g carbohydrate consumption.
Fucoidan (resistance training trial): Participants were randomized to supplement with fucoidan at 1 g/day during six weeks of resistance training.
Fucoidan (animal model GI study): Mice with gastrointestinal dysmotility were treated with fucoidan at 100 and 200 mg per kg body weight and laminarin at 50 and 100 mg per kg body weight. (Animal model only; human equivalent doses not established.)

Despite promising preclinical evidence, comprehensive human studies are still limited. Most clinical trials to date have been small or short-term, and the effects of whole brown algae consumption versus isolated extracts are not fully understood.

7. Safety Considerations and Drug Interactions

Iodine Excess and Thyroid Disruption

Both deficient and excess iodine can have adverse health impacts. Excess iodine exposure through seaweed consumption has been associated with hyperthyroidism, thyroiditis, goiter, and kidney damage. Children and pregnant people may be especially vulnerable to excessive iodine intake due to their smaller thyroid gland size and its possible adverse effects on fetal development. Iodine supports thyroid hormone synthesis, but both low and excessive intake can be problematic depending on context. Notably, certain brown seaweeds in the Laminaria/Saccharina (kombu) genera are among the most iodine-rich foods known.

From seaweed consumption, mean iodine intakes above 20 μg/kg body weight per day were identified among consumers of Kombu and Laver algae. This represents a substantial contribution to total iodine exposure and may exceed safe upper limits for some individuals.

Heavy Metal and Arsenic Accumulation

Some types of seaweed have a high concentration of arsenic and other heavy metals like lead, mercury, and aluminum. Heavy metal concentrations in seaweeds are generally below levels that are toxic for humans; however, the bioaccumulation of arsenic is a concern with continuous seaweed consumption. Most avoidable problems come from unknown iodine content per serving and insufficient contaminant control, especially heavy metals and, for marine materials, inorganic arsenic. The European Food Safety Authority (EFSA) specifically assessed seaweed-related exposure to arsenic, cadmium, lead, and mercury in the European population, identifying that seaweed consumption contributes meaningfully to heavy metal and iodine dietary exposure.

Anticoagulant Interactions (Fucoidan)

Because of its anticoagulant properties, fucoidan may have additive effects with anticoagulants such as warfarin and heparin; due to its anti-thrombotic effects, fucoidan may increase bleeding risk. No major side effects from fucoidan have been reported at typical supplemental doses, though diarrhea was reported in one case, which improved immediately after stopping administration. At moderate doses, fucoidan appears generally safe in the short term. However, animal research suggests very high doses can backfire, actually increasing inflammation and disrupting metabolic markers rather than improving them.

Sodium Load

Eating 5 g a day or more of dried seaweed can create a situation where sodium intake becomes excessively high. This is a practical consideration for individuals on sodium-restricted diets, particularly those with hypertension or cardiovascular disease.

General Safety Assessment

Fucoxanthin and its derivatives are shown to be safe, non-toxic, and readily available upon administration at studied doses. Laminarin has been widely investigated as a functional material in biomedical applications as it is biodegradable, biocompatible, and of low toxicity. The overall safety profile of whole brown algae consumed as food in traditional quantities appears acceptable; concentrated extracts and isolated compounds require greater caution, particularly regarding the iodine burden, anticoagulant properties of fucoidan, and potential for heavy metal accumulation from poorly controlled marine sourcing.

References

Health Conditions

Health conditions that Phaeophyceae may help support.

No conditions available.

Body Systems

Body systems that Phaeophyceae may help support.

No body systems available.